The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 3
Abstract
There are at least 2 types of cannabinoid receptor, CB1 and CB2, both G protein coupled. CB1 receptors are expressed predominantly at nerve terminals and mediate inhibition of transmitter release, whereas CB2 receptors are found mainly on immune cells, their roles including the modulation of cytokine release and of immune cell migration. Endogenous agonists for cannabinoid receptors also exist. These “endocannabinoids” are synthesized on demand and removed from their sites of action by cellular uptake and intracellular enzymic hydrolysis. Endocannabinoids and their receptors together constitute the endocannabinoid system. This review summarizes evidence that there are certain central and peripheral disorders in which increases take place in the release of endocannabinoids onto their receptors and/or in the density or coupling efficiency of these receptors and that this upregulation is protective in some disorders but can have undesirable consequences in others. It also considers therapeutic strategies by which this upregulation might be modulated to clinical advantage. These strategies include the administration of (1) a CB1 and/or CB2 receptor agonist or antagonist that does or does not readily cross the blood brain barrier; (2) a CB1 and/or CB2 receptor agonist intrathecally or directly to some other site outside the brain; (3) a partial CB1 and/or CB2 receptor agonist rather than a full agonist; (4) a CB1 and/or CB2 receptor agonist together with a noncannabinoid, for example, morphine or codeine; (5) an inhibitor or activator of endocannabinoid biosynthesis, cellular uptake, or metabolism; (6) an allosteric modulator of the CB1 receptor; and (7) a CB2 receptor inverse agonist.
Authors and Affiliations
Roger G. Pertwee
Keywords
Related Articles
- EP ID EP681898
- DOI 10.1208/aapsj070364
- Views 102
- Downloads 0
Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs
The Biopharmaceutics Classification System (BCS) categorizes drugs into one of four biopharmaceutical classes according to their water solubility and membrane permeability characteristics and broadly allows the predictio...
Practical Considerations for Dose Selection in Pediatric Patients to Ensure Target Exposure Requirements
Pediatric dosing recommendations are often not based on allometry, despite recognition that metabolic processes in mammals scale to the ¾ power. This report reviews the allometric size model for clearance and its...
Recent Advances in Application of Pharmacogenomics for Biotherapeutics
Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effec...
UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof
Study of crystallization of endogenous surfactant in Eudragit NE30D-Free films and its influence on drug-release properties of controlled-release diphenhydramine HCI pellets coated with Eudragit NE30D
This study investigates the crystallization of the endogenous surfactant nonoxynol 100 in Eudragit NE30D-free films during storage and the influences of nonoxynol 100 on the dissolution of diphenhydramine hydrochloric ac...